{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:43:22Z","timestamp":1773225802521,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40123-026-01336-x","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:15:18Z","timestamp":1772097318000},"page":"1179-1194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergising Macular Function and Structure in Diabetic Macular Oedema to Improve Patient Care: An International Delphi Consensus"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-4771","authenticated-orcid":false,"given":"Christiana","family":"Dinah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Henry","family":"Gabrielle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Insaf","family":"Saffar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloes","family":"Bagijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100519","volume":"4","author":"AR Glassman","year":"2024","unstructured":"Glassman AR, Elmasry MA, Baskin DE, et al. Visual function measurements in eyes with diabetic retinopathy: an expert opinion on available measures. Ophthalmol Sci. 2024;4:100519.","journal-title":"Ophthalmol Sci"},{"key":"1336_CR2","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608\u201322.","journal-title":"Ophthalmology"},{"key":"1336_CR3","unstructured":"National Institute for Health and Care Excellence. Diabetic retinopathy: management and monitoring. NICE guideline NG242. London, https:\/\/www.nice.org.uk\/guidance\/ng242\/resources\/diabetic-retinopathy-management-and-monitoring-pdf-66143953240261 (13 August 2024, Accessed 3 Jan 2025)."},{"key":"1336_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2017.05.014","volume":"180","author":"WC Ou","year":"2017","unstructured":"Ou WC, Brown DM, Payne JF, et al. Relationship between visual acuity and retinal thickness during anti\u2013vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol. 2017;180:8\u201317.","journal-title":"Am J Ophthalmol"},{"key":"1336_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100378","volume":"4","author":"S Vujosevic","year":"2024","unstructured":"Vujosevic S, Chew E, Labriola L, et al. Measuring quality of life in diabetic retinal disease: a narrative review of available patient-reported outcome measures. Ophthalmol Sci. 2024;4:100378.","journal-title":"Ophthalmol Sci"},{"key":"1336_CR6","first-page":"1865","volume":"36","author":"S Srinivasan","year":"2022","unstructured":"Srinivasan S, Sivaprasad S, Rajalakshmi R, et al. Retinal structure\u2013function correlation in type 2 diabetes. Eye (Basingstoke). 2022;36:1865\u201371.","journal-title":"Eye (Basingstoke)"},{"key":"1336_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18157876","volume":"18","author":"MC S\u00e1nchez-Gonz\u00e1lez","year":"2021","unstructured":"S\u00e1nchez-Gonz\u00e1lez MC, Garc\u00eda-Oliver R, S\u00e1nchez-Gonz\u00e1lez JM, et al. Minimum detectable change of visual acuity measurements using ETDRS charts (Early Treatment Diabetic Retinopathy Study). Int J Environ Res Public Health. 2021;18:7876.","journal-title":"Int J Environ Res Public Health"},{"key":"1336_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21:e1004326.","journal-title":"PLoS Med"},{"key":"1336_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/PPA.S347713","volume":"16","author":"A Giocanti-Aur\u00e9gan","year":"2022","unstructured":"Giocanti-Aur\u00e9gan A, Garc\u00eda-Layana A, Peto T, et al. Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study. Patient Prefer Adherence. 2022;16:587\u2013604.","journal-title":"Patient Prefer Adherence"},{"key":"1336_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00125-020-05313-2","volume":"64","author":"DM Broadbent","year":"2021","unstructured":"Broadbent DM, Wang A, Cheyne CP, et al. Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT. Diabetologia. 2021;64:56\u201369.","journal-title":"Diabetologia"},{"key":"1336_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246626","volume":"16","author":"C Dinah","year":"2021","unstructured":"Dinah C, Ghulakhszian A, Sim SY, et al. Aflibercept for treatment-na\u00efve diabetic macula oedema in a multi-ethnic population: real-world outcomes from North West London. PLoS ONE. 2021;16:e0246626.","journal-title":"PLoS ONE"},{"key":"1336_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101219","volume":"97","author":"P-H Gabrielle","year":"2023","unstructured":"Gabrielle P-H, Mehta H, Barthelmes D, et al. From randomised controlled trials to real-world data: clinical evidence to guide management of diabetic macular oedema. Prog Retin Eye Res. 2023;97:101219.","journal-title":"Prog Retin Eye Res"},{"key":"1336_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes. Br J Ophthalmol. 2021;105:216\u201321.","journal-title":"Br J Ophthalmol"},{"key":"1336_CR14","first-page":"22","volume":"19","author":"JS Pollack","year":"2022","unstructured":"Pollack JS, Clark WL, Moshfeghi DM, et al. Discordances in perceptions of shared decision-making among patients with retinal diseases and their care teams. Retin Physician. 2022;19:22\u20136.","journal-title":"Retin Physician"},{"key":"1336_CR15","doi-asserted-by":"publisher","unstructured":"Hillier RJ, Chang A, Matse-Orere A, et al. Surgical capacity in ophthalmology: the unmet need for sustainable solutions. Eye (Basingstoke). Epub ahead of print 2025. https:\/\/doi.org\/10.1038\/s41433-025-04153-x.","DOI":"10.1038\/s41433-025-04153-x"},{"key":"1336_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ. Real-world outcomes of anti-VEGF therapy in diabetic macular oedema: barriers to treatment success and implications for low\/lower-middle-income countries. Ophthalmol Ther. 2023;12:809\u201326.","journal-title":"Ophthalmol Ther"},{"key":"1336_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2474126419834711","volume":"3","author":"SJ Bakri","year":"2019","unstructured":"Bakri SJ, Wolfe JD, Regillo CD, et al. Evidence-based guidelines for management of diabetic macular edema. J Vitreoretin Dis. 2019;3:145\u201352.","journal-title":"J Vitreoretin Dis"},{"key":"1336_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.survophthal.2012.01.004","volume":"57","author":"S Sivaprasad","year":"2012","unstructured":"Sivaprasad S, Gupta B, Crosby-Nwaobi R, et al. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol. 2012;57:347\u201370.","journal-title":"Surv Ophthalmol"},{"key":"1336_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ophtha.2017.10.026","volume":"125","author":"GS Tan","year":"2018","unstructured":"Tan GS, Gan A, Sabanayagam C, et al. Ethnic differences in the prevalence and risk factors of diabetic retinopathy. Ophthalmology. 2018;125:529\u201336.","journal-title":"Ophthalmology"},{"key":"1336_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ajo.2020.09.042","volume":"222","author":"P Osathanugrah","year":"2021","unstructured":"Osathanugrah P, Sanjiv N, Siegel NH, et al. The impact of race on short-term treatment response to bevacizumab in diabetic macular edema. Am J Ophthalmol. 2021;222:310\u20137.","journal-title":"Am J Ophthalmol"},{"key":"1336_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/IAE.0000000000003283","volume":"4","author":"V Chaudhary","year":"2022","unstructured":"Chaudhary V, Matonti F, Zarranz-Ventura J, et al. Impact of fluid compartments on functional outcomes for patients with neovascular age-related macular degeneration: a systematic literature review. Retina. 2022;4:589\u2013606.","journal-title":"Retina"},{"key":"1336_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.oret.2019.07.007","volume":"3","author":"CC Wykoff","year":"2019","unstructured":"Wykoff CC. Thresholds for initiating treatment of eyes with diabetic macular edema and good vision: consideration of DRCR.Net protocol V results. Ophthalmol Retina. 2019;3:917\u20139.","journal-title":"Ophthalmol Retina"},{"key":"1336_CR23","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s00417-024-06558-y","volume":"262","author":"S Nakao","year":"2024","unstructured":"Nakao S, Kusuhara S, Murakami T. Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology. Graefes Arch Clin Exp Ophthalmol. 2024;262:3749\u201359.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1336_CR24","unstructured":"The National Institute of Health and Care Excellence. Overview: Ranibizumab for treating diabetic macular oedema (ta274), https:\/\/www.nice.org.uk\/guidance\/ta274 (2023, Accessed 20 Mar 2025)."},{"key":"1336_CR25","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41433-022-01935-5","volume":"36","author":"C Dinah","year":"2022","unstructured":"Dinah C, Myers S, Pushpoth S, et al. Revisiting NICE guidelines for initiation of intravitreal anti-VEGF therapy for centre-involving diabetic macular oedema: a survey of current interpretation in the United Kingdom. Eye. 2022;36:1832\u20134.","journal-title":"Eye"},{"key":"1336_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Campbell J, Dugel PU, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye. 2020;34:480\u201390.","journal-title":"Eye"},{"key":"1336_CR27","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.2147\/OPTH.S273564","volume":"14","author":"D Bhagat","year":"2020","unstructured":"Bhagat D, Kirby B, Bhatt H, et al. Patient preferences associated with anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2020;14:2975\u201382.","journal-title":"Clin Ophthalmol"},{"key":"1336_CR28","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bjo-2023-323900","volume":"108","author":"F Vingopoulos","year":"2024","unstructured":"Vingopoulos F, Baldwin G, Katz R, et al. Associations of quantitative contrast sensitivity with vascular metrics on widefield swept-source OCT angiography across stages of diabetic retinopathy. Br J Ophthalmol. 2024;108:1708\u201315.","journal-title":"Br J Ophthalmol"},{"key":"1336_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00417-023-06272-1","volume":"262","author":"HA R\u00edos","year":"2024","unstructured":"R\u00edos HA, L\u00f6vestam-Adrian M, Plainis S, et al. Additional measures of macular function beyond visual acuity. Graefes Arch Clin Exp Ophthalmol. 2024;262:1723\u201336.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1336_CR30","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00417-022-05944-8","volume":"261","author":"S Dieke","year":"2023","unstructured":"Dieke S, Wurche S, Ruebsam A, et al. Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME. Graefes Arch Clin Exp Ophthalmol. 2023;261:1823\u201333.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1336_CR31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/IAE.0000000000001316","volume":"37","author":"IJ Su\u00f1er","year":"2017","unstructured":"Su\u00f1er IJ, Bressler NM, Varma R, et al. Responsiveness of the national eye institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema: evidence from the RIDE and RISE trials. Retina. 2017;37:1126\u201333.","journal-title":"Retina"},{"key":"1336_CR32","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1167\/iovs.16-20950","volume":"58","author":"EK Fenwick","year":"2017","unstructured":"Fenwick EK, Khadka J, Pesudovs K, et al. Diabetic retinopathy and macular edema quality-of-life item banks: development and initial evaluation using computerized adaptive testing. Invest Ophthalmol Vis Sci. 2017;58:6379\u201387.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1336_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2021.11.020","volume":"238","author":"O Nanegrungunk","year":"2022","unstructured":"Nanegrungunk O, Gu SZ, Bressler SB, et al. Correlation of change in central subfield thickness and change in visual acuity in neovascular AMD: Post-hoc analysis of VIEW 1 and 2. Am J Ophthalmol. 2022;238:97\u2013102.","journal-title":"Am J Ophthalmol"},{"key":"1336_CR34","volume":"12","author":"A Markan","year":"2020","unstructured":"Markan A, Agarwal A, Arora A, et al. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol. 2020;12:2515841420950513.","journal-title":"Ther Adv Ophthalmol"},{"key":"1336_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000527345","volume":"245","author":"O Habra","year":"2022","unstructured":"Habra O, Gallardo M, Meyer zu Westram T, et al. Evaluation of an artificial intelligence-based detector of sub- and intraretinal fluid on a large set of optical coherence tomography volumes in age-related macular degeneration and diabetic macular edema. Ophthalmologica. 2022;245:516\u201327.","journal-title":"Ophthalmologica"},{"key":"1336_CR36","first-page":"6285","volume":"65","author":"RE Hogg","year":"2024","unstructured":"Hogg RE, Anderson RS, Peto T, et al. Selecting combinations of visual function measures to identify severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2024;65:6285.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01336-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:09:48Z","timestamp":1773151788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01336-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01336-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors received honoraria from Roche while undertaking this study. Roche commissioned Triducive Partners Limited to facilitate the project and analyse the responses to the consensus statements in line with the Delphi methodology. The authors state the following conflicts of interest: Christiana Dinah: Consultancy and Advisory boards: Roche, Boehringer Ingelheim, Bayer, AbbVie, Johnson & Johnson, Eyepoint Pharmaceuticals, Ocular Therapeutix, Alimera Sciences, Astellas, Apellis. Speaker fees: Roche, Boehringer Ingelheim, Bayer, Topcon Ltd, AbbVie, Apellis, Astellas. Travel and conference support: Roche, Boehringer Ingelheim, Apellis. Andrew Chang: Consultancy and Advisory boards: Roche, Bayer, Novartis, Alcon, Zeiss, Apellis, Astellas, Opthea. Pierre-Henry Gabrielle: Received travel expenses from AbbVie, Bayer, and Novartis, and is a medical consultant for Astellas, Novartis, Horus pharma, Roche, Allergan\/Abbvie, and Bayer. Rishi Singh: Personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch & Lomb, Zeiss, Alcon, and Regeneron, and research grants from Janssen. Javier Zarranz-Ventura: Abbvie, Adverum, Alcon, Alimera Sciences, Bausch & Lomb, Bayer, Brill Pharma, DORC, Esteve, Novartis, Roche, Sandoz, Topcon, Zeiss. Insar Saffar: Personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch & Lomb, Zeiss, Alcon, and Regeneron, research grants from Janssen, employee of F. Hoffmann-La Roche Ltd. Marloes Bagijn: Employee of F. Hoffmann-La Roche Ltd. Aude Ambresin: Abbvie, Apellis, Astellas, Bayer, Novartis, Optovue, RetinAI, Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics approval was not sought because neither the assigned interventions nor the outcomes assessed were related to the health of participants, and it was a non-interventional opinion-based Delphi process involving healthcare practitioners, with no collection of sensitive or personally identifiable data. In accordance with the UK Governance Arrangements for Research Ethics Committees (GAfREC) section 2.3, research involving clinical staff recruited by virtue of their professional role does not require research ethics committee review unless it involves access to confidential information or raises issues of professional performance. In accordance with the Declaration of Helsinki, all respondents involved in the survey within study were informed of the research purpose and that their data would remain anonymous. Their consent was assumed through the completion and submission of their survey responses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}